芪蓉润肠口服液治疗老年功能性便秘有效性和安全性的Meta分析  

Efficiency and Safety of Qirongrunchang Oral in Elderly Patients with Functional Constipation:A Meta-analysis

作　　者：陈浩洋[1] 李芳斓 林鸿成 耿朋博 黄培颖 魏志军[1] CHEN Haoyang;LI Fanglan;LIN Hongcheng;GENG Pengbo;HUANG Peiying;WEI Zhijun(Shenzhen Traditional Chinese Medicine Hospital,Shenzhen 518000,China;The Fourth Clinical Medical School,Guangzhou University of Chinese Medicine,Guangzhou 510006,China)

机构地区：[1]深圳市中医院,广东深圳518000 [2]广州中医药大学第四临床医学院,广东广州510006

出　　处：《中国民族民间医药》2022年第21期98-104,共7页Chinese Journal of Ethnomedicine and Ethnopharmacy

基　　金：深圳市科技创新基金(项目编号:JCYJ20160428175517213)。

摘　　要：目的:应用成对Meta分析评价芪蓉润肠口服液治疗老年功能性便秘的临床有效性及安全性。方法:运用计算机检索中国知网、万方、维普、中国生物医学文献数据库、Pub Med、Cochrane library和Embase数据库中关于芪蓉润肠口服液治疗老年功能性便秘的随机对照实验。应用Cochrane 5.1.0版系统评价手册进行文献质量评估,并通过R软件的Meta包进行成对Meta分析。结果:共纳入4篇文献,包括367名患者。Meta分析结果显示:口服芪蓉润肠口服液治疗老年功能性便秘的总有效率与西药相当[RR=1.05,95%CI(0.87,1.25)],而在西药的基础上联用芪蓉润肠口服液对比单纯的西药治疗老年功能性便秘,能显著提高总有效率[RR=1.35,95%CI(1.17,1.57)],且两组间的不良反应情况无统计学差异[RR=0.88,95%CI(0.33,2.32)]。结论:在治疗老年功能性便秘患者的时候,芪蓉润肠口服液与西药效果相当,而在西药的基础上联用芪蓉润肠口服液,能够显著地提升治疗效果,但此结论仍需更多前瞻性多中心大样本的随机对照实验予以证实。Objective We hopes to adopt meta-analysis to evaluate the efficacy and safety of qirongrunchang oral(QRRC)in the treatment of elderly patients with functional constipation(EPFC).Method Databases including CNKI,Wan-Fang databases,VIP,Sino Med,Pub Med,Cochrane library,and Embase were searched by computer.Only randomized controlled trials(RCT)about QRRC in the treatment of EPFC were included.The methodological quality of the included studies was evaluated according to the bias risk assessment tool in Cochrane5.1.0.Pair meta-analysis was carried out using the Meta package of the R software.Results 4 articles and367 patients were included.Meta-analysis reveals that there is no significant difference between the interventions of QRRC and western medicine in the treatment of EPFC[RR=1.05,95%CI(0.87,1.25)].However,the efficacy of QRRC combined with western medicine in treating EPFC was significantly higher than that of western medicine alone[RR=1.35,95%CI(1.17,1.57)],and there is no statistical difference in adverse effects between the two groups[RR=0.88,95%CI(0.33,2.32)].Conclusions No evidence for differential treatment effects between QRRC and western medicine was found in the treatment of EPFC,but to some extent,the therapeutic effects could be improved remarkably by western medicine combined with QRRC.Additional prospective,multicenter RCT with large sample sizes are needed to confirm these findings.

关 键 词：芪蓉润肠口服液 西药 老年功能性便秘 总有效率 不良反应率 

分 类 号：R256.35[医药卫生—中医内科学]